The BERG Interrogative Biology® is a disruptive platform for use by biopharma and health systems. It is based on hypothesis-free, data-driven philosophy applied to biomedical and outcome research. Interrogative Biology® insight and findings are typically first-in-class molecular entities with wide freedom to operate in specific disease area. This platform utilizes human biological samples (immortalized cell lines, patient derived cells, biofluids or tissues) and employs a number of high-throughput molecular profiling technologies. It goes beyond the traditionally accepted genomics, performing deep molecular phenotyping in proteomics, lipidomics and metabolomics. Applications of Interrogative Biology® in biopharma include, but are not limited to, target discovery, mechanism of action discovery, drug repositioning, and biomarker discovery. While the platform is therapeutic area agnostic, BERG has successfully applied the platform in diseases (therapeutics, biomarkers, and mechanisms in oncology, neurology, metabolic disease, inflammation), and clinical insights/outcomes (RWD/RWE, Medicare/Medicaid).

The perturbation biology captures molecular plasticity between non-disease and disease continuum during model building. Patient derived material provides relevance of biological insights identified by this method to disease. High-throughput, high-density multiomic profiling provides granular molecular fingerprint. This data is the input for the AI component of the platform: bAIcis®.

bAIcis®, the predictive tool of the platform, is data source agnostic and can manage extremely large datasets. bAIcis® can infer Bayesian networks from the observed variability in the data. The algorithms embedded within bAIcis® integrate molecular high-throughput data with phenotypic low-throughput data and clinical information to generate causal networks.

At BERG, we have used the Interrogative Biology® Platform for:

• Target Identification
• Biomarker Identification
• Mechanism of Action (MOA) and underlying biology

This platform has been key in development of the clinical trial strategy for our flagship molecule: BPM31510.